Medicare GLP-1 Coverage Adds 700,000 Senior Users, Lilly Claims 70% Share
Eli Lilly's CEO says 700,000 new seniors began GLP-1 drugs after Medicare coverage launched in July, with Lilly capturing roughly 70% of those patients.
Eli Lilly's chief executive says 700,000 seniors have started taking GLP-1 medications since Medicare began covering the drug class in July, with the company's own treatments accounting for approximately 70% of that newly insured patient population, according to the latest figures disclosed by the drugmaker.
The data point offers one of the clearest early signals yet of how federal insurance expansion is reshaping access to a category of medicines that had largely been out of reach for older Americans on fixed incomes. Prior to the Medicare coverage change, cost remained a significant barrier for many seniors seeking GLP-1 therapies.
Read more White House Press Pool Suspends TV Coverage of Trump →
Lilly's dominant share of the new Medicare cohort underscores the competitive position the Indianapolis-based pharmaceutical giant holds in the GLP-1 market, where it competes against rivals including Novo Nordisk. The 70% figure suggests Lilly's offerings are being preferentially prescribed or selected within the Medicare formulary landscape.
The enrollment numbers are being watched closely by policymakers, insurers, and investors as a gauge of the real-world impact of the coverage expansion. If adoption continues at pace, the financial and clinical implications for the Medicare program could be substantial over coming years. Analysts have noted that broader GLP-1 access among seniors raises longer-term questions about Medicare drug spending budgets.
Continue reading at Business News.
